Neurocrine Biosciences (NBIX) Tops Q4 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
February 4, 2020 4:01 PM ESTSAN DIEGO, Feb. 4, 2020 /PRNewswire/ --Â Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2019 and provided full-year 2020 financial expense guidance.
"I am very pleased with the accomplishments of Neurocrine Biosciences this past year, including our quarterly and full-year business results. We anticipate an exciting year... More
